Combined cranberry supplementation and weight loss diet in non-alcoholic fatty liver disease: a double-blind placebo-controlled randomized clinical trial

Hormoznejad R., Shahi M. M., RAHIM F., Helli B., Alavinejad P., Sharhani A.

INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION, vol.71, no.8, pp.991-1000, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 71 Issue: 8
  • Publication Date: 2020
  • Doi Number: 10.1080/09637486.2020.1746957
  • Journal Name: INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Agricultural & Environmental Science Database, Aquatic Science & Fisheries Abstracts (ASFA), BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, CINAHL, EMBASE, Food Science & Technology Abstracts, MEDLINE, SportDiscus, Veterinary Science Database
  • Page Numbers: pp.991-1000
  • Kocaeli University Affiliated: No

Abstract

A double-blind placebo-controlled randomised clinical trial was conducted on 41 patients with non-alcoholic fatty liver disease (NAFLD). Participants were randomly allocated to receive either a cranberry supplement or a placebo for 12 weeks. Both groups were assigned to follow a weight loss diet. At the end of the study, alanine aminotransferase and insulin decreased significantly in both groups (p < .05); however, this reduction was significantly greater in the cranberry group than in the placebo group (p < .05). Significant improvements in insulin resistance were observed in the cranberry group and between the two groups (p < .001 and p = .020, respectively). Also, there was an improvement in steatosis grade and anthropometric measurements in both groups (p < .05), and there was no significant difference between the two groups in regard to these factors (p > .05). It seems that 288 mg of cranberry extract might improve managing NAFLD, which is equivalent to 26 g of dried cranberry.